Background: Psoriasis in human immunodeficiency virus (HIV)-positive patients may be
severe. Physicians may be tentative to use biologics in HIV-infected patients. Objective: We …

Background: The management of psoriatic disease in HIV-positive patients is challenging.
Psoriasis in HIV-positive patients is often severe, progressive, and resistant to first-and …

Background: The management of HIV-positive patients with psoriasis is controversial and
limited to individual cases or short series of patients. Objectives: To evaluate the safety and …

Methods To investigate the efficacy and safety of systemic immunosuppressive therapies for
psoriatic disease in HIV-positive individuals, a PubMed search of articles indexed for …

Background Clinical trial data have shown guselkumab, an interleukin-23 inhibitor, to be
efficacious and safe for the treatment of psoriasis. However, there is very little real-world …

Here we describe a case of a 39-year-old male with HIV and a 20-year history of
generalized plaque psoriasis and psoriatic arthritis. The patient had been refractory to all …

Psoriasis is a common, chronic, immune-mediated inflammatory skin disease that may
cause psychosocial comorbidities in affected population. The prevalence of psoriasis in HIV …

Little information is available from real-life studies evaluating the efficacy of guselkumab in
moderate-to-severe psoriasis. In this real-life study, we retrospectively examined a database …

Background Real-world data for guselkumab, the first interleukin-23 inhibitor approved to
treat moderate-to-severe psoriasis, are scarce. This study represents the first 60-week, real …

Introduction: Psoriasis is a chronic immune mediated disease in which the interplay of T
cells and keratinocytes seems to play a key role. In this context, the interleukin (IL)-23/IL-17 …